Omalizumab in chronic spontaneous urticaria
نویسندگان
چکیده
منابع مشابه
Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
Background Chronic spontaneous urticaria (CSU) is more common in adults, especially middle-aged women. The condition resolves spontaneously within 6 months in 30 to 55% of patients but can persist for years in others. It has a devastating effect on the quality of life of those who experience it. Although the mechanisms are not fully elucidated, anti IgE recombinant humanized monoclonal (Omalizu...
متن کاملOmalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
BACKGROUND Current guidelines on chronic spontaneous urticaria (CSU) suggest a treatment based on a 3-step approach that aims at total symptom control, starting with H1-antihistamines. However, a significant number of patients present an antihistamine-resistant urticaria that must be treated with an alternative third-line therapy such as omalizumab. METHODS Patients with a history of CSU who ...
متن کاملProfile of omalizumab in the treatment of chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely...
متن کاملOmalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
BACKGROUND Chronic spontaneous urticaria (CSU) is a common, debilitating disease that is frequently resistant to standard therapy. Omalizumab, anti-immunoglobulin-E humanized monclonal antibody, was recently shown to be effective in treating resistant CSU. OBJECTIVES To investigated the treatment of CSU with omalizumab in Israel. METHODS We conducted a multicenter retrospective analysis of ...
متن کاملOmalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS In this phase 3, multicenter, ran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Research in Dermatology
سال: 2018
ISSN: 2455-4529
DOI: 10.18203/issn.2455-4529.intjresdermatol20183170